GSK’s Victory In Zofran Product Liability Cases Shows Power Of Communications With US FDA
Executive Summary
In granting GlaxoSmithKline’s motion for summary judgment in multidistrict litigation, judge notes FDA rejected requests to change warning label about use in pregnant women multiple times and would not have approved warnings sought by plaintiffs.
You may also be interested in...
Merck Freed From Fosamax Product Liability Suits Based On US FDA Complete Response Letter
District court dismisses more than 500 cases alleging Merck failed to warn of the risks of its osteoporosis drug, following path set by US Supreme Court in its ruling on the litigation three years ago.
GSK Loses Bid To Get US FDA To Change Zofran Label, But May Prevail On Preemption Defense Anyway
Agency denies GlaxoSmithKline’s citizen petition requesting review of information about Zofran’s use in pregnancy. But GSK says agency has ‘clearly communicated its position that birth defect warnings are not warranted for Zofran.’
US FDA Takes Star Turn In Recent Product Liability Lawsuits
Agency’s direct involvement in pharma product liability litigation is one of the most striking developments in the field over the past year. Chart of 16 cases in multidistrict litigation shows status of settlements and upcoming bellwether trials.